tbuckley/cabot-search huggingface dataset:
Pre-eclampsia is linked to small increase in risk of cardiomyopathy in longer term
Authors: Jacqui Wise
Journal: BMJ (2016)

Women with a history of pre-eclampsia or gestational hypertension have a small but statistically significant increased risk of cardiomyopathy, which persists for more than five years after pregnancy, a Danish study published in JAMA has found.1

Women with pre-eclampsia are already known to have a greatly increased risk of cardiomyopathy in the peripartum period—the last month of pregnancy until five months after delivery—but it is not known whether hypertensive disorders of pregnancy …
Hepatitis B : The evolution of the clevudine resistant HBV during the rescue therapy (초)
Authors: Ei Leen Yoon, Hyung Joon Yim, Ji Won Hwang, Chang Seok Ki, Hyun Jung Lee, Sun Jae Lee, Sang Jun Suh, Ji Hoon Kim, Jong Eun Yeon, Sang Woo Lee, Soon Ho Um, Kwan Soo Byun, Jai Hyun Choi
Journal: Clinical and Molecular Hepatology (2011)
Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models
Authors: Abin You, Manqing Cao, Zhigui Guo, Bingfeng Zuo, Junrong Gao, Hongyuan Zhou, Huikai Li, Yunlong Cui, Feng Fang, Wei Zhang, Tianqiang Song, Qiang Li, Xiaolin Zhu, Haifang Yin, Huichuan Sun, Ti Zhang
Journal: Journal of Hematology & Oncology (2016)

Sorafenib is recognized as a standard treatment for advanced hepatocellular carcinoma (HCC). However, many patients have to adopt dose reduction or terminate the use of sorafenib because of side effects. In addition, a large number of patients are resistant to sorafenib. Thus, it is essential to investigate the underlying mechanisms of the resistance to sorafenib and seek potential strategy to enhance its efficacy. The protein expression of hypoxia-inducible factors (HIF)-2α, 30-kDa HIV Tat-interacting protein (TIP30), E-cadherin, N-cadherin, and pAMPK was detected by Western blot. Cell viability assays were performed to study the influence of metformin and sorafenib on cell proliferation. Annexin V-FITC apoptosis assays were used to detect the influence of metformin and sorafenib on cell apoptosis. The relationship between HIF-2α and TIP30 was studied using gene silencing approach and chromatin immunoprecipitation assay. To investigate the effect of metformin and sorafenib on postoperative recurrence and lung metastasis of HCC in tumor-bearing mice, the mice were orally treated either with metformin or sorafenib once a day for continuous 37 days after the operation to remove the lobe where the tumor was implanted. CD31, Ki67, and TUNEL were examined by immunohistochemistry. Our study demonstrated that metformin synergized with sorafenib reduced HIF-2α expression as examined by Western blot. Gene silencing approach indicated TIP30 was upregulated after knocking-down of HIF-2α and chromatin immunoprecipitation assay revealed that HIF-2α could bind to TIP30 promoter under hypoxic condition. Cell Counting Kit-8 (CCK8) cell viability assay and Annexin V-FITC apoptosis assay showed that metformin in combination with sorafenib suppressed cell proliferation and promoted cell apoptosis. Besides, combined therapy suppressed epithelial-mesenchymal transition (EMT) process both in vitro and in vivo. Moreover, metformin in combination with sorafenib significantly minimized postoperative recurrence and lung metastasis of HCC in orthotopic mouse model. Combined therapy inhibited CD31 and Ki67 expression but promoted TUNEL expression. Metformin may potentially enhance the effect of sorafenib to inhibit HCC recurrence and metastasis after liver resection by regulating the expression of HIF-2α and TIP30.
How MicroRNAs Are Involved in Splitting the Mind
Authors: Li-Huei Tsai, Sandra Siegert
Journal: JAMA Psychiatry (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Impact of Asthma Exacerbations on Health Status in Patients with Severe Asthma
Authors: Sarah Cockle, Linda Nelsen, Miriam Kimel, Frank C. Albers, Paul Jones
Journal: Journal of Allergy and Clinical Immunology (2016)

Asthma exacerbations constitute a considerable part of disease burden in patients with severe uncontrolled asthma. However, the impact of exacerbations is challenging to quantify. The St George's Respiratory Questionnaire (SGRQ), a measure of health status in obstructive airway disease, was measured at baseline and end of treatment in a 32 week phase III clinical trial of mepolizumab for treatment of severe asthma with a history of exacerbations (MENSA). In this post-hoc analysis, we examined the impact of exacerbations in 2 ways (1) baseline SGRQ scores by exacerbation history (≤2 compared with >2) and (2) change in SGRQ scores for subjects with and without exacerbations during treatment. All patients entering the trial had a history of at least two severe asthma exacerbations in the prior 12 months. Among subjects with a history of ≤2 exacerbations, mean baseline SGRQ total score was 42.5 compared to 49.4 for those a history of >2 exacerbations (p<0.0001). Among patients not experiencing an exacerbation during the study, SGRQ total score at 32 weeks was 28.5 compared to 41.5 for subjects experiencing >1 exacerbations during study treatment (p<0.0001) with changes of -15.4 and -8.0, respectively. Similar patterns were observed for SGRQ domain scores. The observed differences in SGRQ total and domain scores for subjects with history of exacerbations at baseline or experiencing an exacerbation during the study substantially exceeded the accepted minimum clinically important difference of 4. These differences in SGRQ score demonstrate a substantial health impact of exacerbations. Funding: GSK (NCT01691521).
Online Reviews of Physicians—Reply
Authors: Dane Hill, Steven R. Feldman
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Incidence and Survival Outcomes Of Extramedullary Myeloma
Authors: S. Vincent Rajkumar, Angela Dispenzieri, Martha Q Lacy, Morie A Gertz, Francis K Buadi, David Dingli, Suzanne R Hayman, Prashant Kapoor, Arleigh McCurdy, Nelson Leung, Stephen Russell, John A Lust, Steven R Zeldenrust, Yi Lin, Robert Kyle, Macp, Shaji K Kumar
Journal: Blood (2013)
A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events
Authors: Matthew M Heeney, Carolyn C Hoppe, Miguel R Abboud, Baba Inusa, Julie Kanter, Bernhards Ogutu, Patricia B Brown, Lori E Heath, Joseph A Jakubowski, Chunmei Zhou, Dmitry Zamoryakhin, Tsiri Agbenyega, Raffaella Colombatti, Hoda M Hassab, Videlis N Nduba, Janet N Oyieko, Nancy Robitaille, Catherine I Segbefia, David C Rees
Journal: New England Journal of Medicine (2015)

Sickle cell anemia is an inherited blood disorder that is characterized by painful vaso-occlusive crises, for which there are few treatment options. Platelets mediate intercellular adhesion and thrombosis during vaso-occlusion in sickle cell anemia, which suggests a role for antiplatelet agents in modifying disease events.Children and adolescents 2 through 17 years of age with sickle cell anemia were randomly assigned to receive oral prasugrel or placebo for 9 to 24 months. The primary end point was the rate of vaso-occlusive crisis, a composite of painful crisis or acute chest syndrome. The secondary end points were the rate of sickle cell-related pain and the intensity of pain, which were assessed daily with the use of pain diaries.A total of 341 patients underwent randomization at 51 sites in 13 countries across the Americas, Europe, Asia, and Africa. The rate of vaso-occlusive crisis events per person-year was 2.30 in the prasugrel group and 2.77 in the placebo group (rate ratio, 0.83; 95% confidence interval, 0.66 to 1.05; P=0.12). There were no significant differences between the groups in the secondary end points of diary-reported events. The safety end points, including the frequency of bleeding events requiring medical intervention, of hemorrhagic and nonhemorrhagic adverse events that occurred while patients were taking prasugrel or placebo, and of discontinuations due to prasugrel or placebo, did not differ significantly between the groups.Among children and adolescents with sickle cell anemia, the rate of vaso-occlusive crisis was not significantly lower among those who received prasugrel than among those who received placebo. There were no significant between-group differences in the safety findings. (Funded by Daiichi Sankyo and Eli Lilly; ClinicalTrials.gov number, NCT01794000.).
Frog Lysozyme. IV. Isozymes of Lysozyme and the Lucke Renal Adenocarcinoma 2 3
Authors: George W. Nace, David S. Ostrovsky
Journal: JNCI Journal of the National Cancer Institute (1977)

The normal kidney of the frog Rana pipiens contains eight isozymes of lysozyme. Three of these, however, were not present in five Lucké renal adenocarcinomas. No isozymes were found to be unique to the tumor kidneys. Of the five isozymes detected in tumor kidneys, only one was uniformly present, a second was present in four of five tumors, and the appearance of the other three was highly variable, although no tumor kidney contained all of them. The uniform absence of the three isozymes and the variable distribution of the other five among the tumors attested to the metabolic uniqueness of this tumor and was consistent with a prior hypothesis concerning the role of lysozyme in the etiology of this herpesvirus-induced tumor.
A phase 1b study of Trebananib plus Paclitaxel and Trastuzumab or Capecitabine and Lapatinib in patients with HER2+ locally recurrent or metastatic breast cancer
Authors: P.A. Kaufman, G. Freyer, M. Kemeny, A. Gonçalves, Guy Jerusalem, A. Stopeck, N. Vrindavanam, F. Dalenc, N. Nanayakkara, B. Wu, C.A. Pickett, H. Wildiers
Journal: Cancer Research (2015)
Update: Providing Quality Family Planning Services — Recommendations from CDC and the U.S. Office of Population Affairs, 2015
Authors: Loretta Gavin, Karen Pazol
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

In 2014, CDC published Providing Quality Family Planning Services: Recommendations of CDC and the U.S. Office of Population Affairs (QFP), which describes the scope of services that should be offered in a family planning visit, and how to provide those services (e.g., periodicity of screening, which persons are considered to be at risk, etc.). The sections in QFP include Contraceptive Services, Pregnancy Testing and Counseling, Clients Who Want to Become Pregnant, Basic Infertility Services, Preconception Health Services, Sexually Transmitted Disease Services, Related Preventive Health Services, and Screening Services for Which Evidence Does Not Support Screening.
Recovery Curves for Pediatric Burn Survivors
Authors: Lewis E. Kazis, Austin F. Lee, Mary Rose, Matthew H. Liang, Nien-Chen Li, Xinhua S. Ren, Robert Sheridan, Janet Gilroy-Lewis, Fred Stoddard, Michelle Hinson, Glenn Warden, Kim Stubbs, Patricia Blakeney, Walter Meyer, Robert McCauley, David Herndon, Tina Palmieri, Kate Mooney, David Wood, Frank Pidcock, Debra Reilly, Marc Cullen, Catherine Calvert, Colleen M. Ryan, Jeffrey C. Schneider, Marina Soley-Bori, Ronald G. Tompkins
Journal: JAMA Pediatrics (2016)

<h3>Importance</h3> Patient-reported outcomes serving as benchmarks for recovery of pediatric burn survivors are lacking, and new approaches using longitudinal cohorts for monitoring their expected recovery based on statistical models are needed for patient management during the early years following the burn. <h3>Objective</h3> To describe multidimensional patient-reported outcomes among pediatric burn survivors younger than 5 years to establish benchmarks using recovery curve methods. <h3>Design, Setting, and Participants</h3> Prospective cohort study of pediatric burn survivors younger than 5 years at 12 burn centers. Age-matched nonburned reference groups were studied to define expected results in normal growth and development. The Burn Outcomes Questionnaire for children aged 0 to 5 years (BOQ<sub>0-5</sub>) was administered to parents of children who had burns and were younger than 5 years. Mixed models were used to generate 48-month recovery curves for each of the 10 BOQ<sub>0-5</sub>domains. The study was conducted between January 1999 and December 2008. <h3>Main Outcomes and Measures</h3> The 10 BOQ<sub>0-5</sub>domains including play, language, fine motor skills, gross motor skills, emotional behavior, family functioning, pain/itching, appearance, satisfaction with care, and worry/concern up to 48 months after burn injury. <h3>Results</h3> A total of 336 pediatric burn survivors younger than 5 years (mean [SD] age, 2.0 [1.2] years; 58.4% male; 60.2% white, 18.6% black, and 12.0% Hispanic) and 285 age-matched nonburned controls (mean [SD] age, 2.4 [1.3] years; 51.1% male; 67.1% white, 8.9% black, and 15.0% Hispanic) completed the study. Predicted scores improved exponentially over time for 5 of the BOQ<sub>0-5</sub>domains (predicted scores at 1 month vs 24 months: play, 48.6 vs 52.1 [<i>P</i> = .03]; language, 49.2 vs 54.4 [<i>P</i> &lt; .001]; gross motor skills, 48.7 vs 53.0 [<i>P</i> = .002]; pain/itching, 15.8 vs 33.5 [<i>P</i> &lt; .001]; and worry/concern, 31.6 vs 44.9 [<i>P</i> &lt; .001]). Pediatric burn survivors had higher scores in language, emotional behavior, and family functioning domains compared with healthy children in later months. <h3>Conclusions and Relevance</h3> This study demonstrates significant deficits in multiple functional domains across pediatric burn survivors compared with controls. Recovery curves can be used to recognize deviation from the expected course and tailor care to patient needs.
Circulating N-Linked Glycoprotein Acetyls and Longitudinal Mortality Risk
Authors: Patrick R. Lawler, Akintunde O. Akinkuolie, Paulette D. Chandler, M. Vinayaga Moorthy, Martin J. Vandenburgh, Debra A. Schaumberg, I-Min Lee, Robert J. Glynn, Paul M Ridker, Julie E. Buring, Samia Mora
Journal: Circulation Research (2016)

Rationale: Circulating glycoprotein N-acetyl glucosamine residues have recently been associated with incident cardiovascular disease and diabetes mellitus. Objective: Using a plasma glycan biosignature (GlycA) to identify circulating N-acetyl glycan groups, we examined the longitudinal association between GlycA and mortality among initially healthy individuals. Methods and Results: We quantified GlycA by 400 MHz 1 H nuclear magnetic resonance spectroscopy in 27 524 participants in the Women’s Health Study (NCT00000479). The primary outcome was all-cause mortality. We replicated the findings in an independent cohort of 12 527 individuals in the Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial (NCT00239681). We also undertook secondary examination of cardiovascular disease and cancer mortality in the Women’s Health Study. In the Women’s Health Study, during 524 515 person-years of follow-up (median, 20.5 years), there were 3523 deaths. Risk factor–adjusted multivariable Cox proportional hazard ratio (95% confidence interval) per SD increment in GlycA for all-cause mortality was significantly increased at 5 years (1.21 [1.06–1.40]) and during maximal follow-up (1.14 [1.09–1.16]). Similar risk for all-cause mortality was observed in the replication cohort (1.33 [1.21–1.45]). In the Women’s Health Study, risk of cardiovascular disease mortality was increased at 5 years (1.43 [1.05–1.95]) and during maximal follow-up (1.15 [1.04–1.26]) and of cancer mortality at 5 years (1.23 [1.02–1.47]) and during maximal follow-up (1.08 [1.01–1.16]). Examination of correlations and mortality associations adjusted for high-sensitivity C-reactive protein, fibrinogen, and intercellular adhesion molecule-1, suggested that GlycA reflects summative risk related to multiple pathways of systemic inflammation. Conclusions: Among initially healthy individuals, elevated baseline circulating glycoprotein N-acetyl methyl groups were associated with longitudinal risk of all-cause, cardiovascular, and cancer mortality.
Efficacy and safety of a two drug-combination regimen for cancer-related cachexia in the clinical practice.
Authors: Clelia Madeddu, Mariele Dessi, Laura Orgiano, Giorgia Antoni, Roberto Serpe, Itaru Omoto, Maria Chiara Cau, Antonio Macciò, Giovanni Mantovani
Journal: Journal of Clinical Oncology (2013)

e20556 Background: To test the safety and efficacy of a combination treatment (including nutraceuticals, i.e. quercetin, alpha lipoic acid and curcumin) with carnitine + celecoxib for the treatment of cancer-related anorexia/cachexia syndrome (CACS) in the clinical practice. Primary endpoints: safety, increase of lean body mass (LBM) and improvement of quality of life. Secondary endpoints: increase of physical performance (tested by grip strength and 6-min walk test, 6MWT) and decrease of inflammation (assessed by serum levels of IL-6 and Glasgow prognostic score, GPS). Methods: Outpatients with advanced cancer at different sites with CACS (i.e. loss of body weight &gt;5% of the pre-illness or ideal weight in the previous 3 months) were eligible to receive: L-carnitine 4 g/day + Celecoxib 300 mg/day. All patients received as basic treatment polyphenols 300 mg/day, lipoic acid 300 mg/day, carbocysteine 2.7 g/day, Vitamin E, A, C, all orally. Treatment duration was 4 months. Results: From June 2011 to April 2012, 75 patients with advanced cancer (all stage IV) at different sites were enrolled: 40 completed the treatment and were evaluable (mean age 65 ± 9.6, range 32-82 years). Results showed a significant increase of LBM (by dual-energy X-ray absorptiometry and by L3 computed tomography) from baseline as well as physical performance assessed by 6MWT. Quality of life (assessed by EORTC-QLQ-C30) as well as fatigue (assessed by MFSI-SF) also improved significantly. ECOG PS and GPS decreased significantly. The treatment was safe, no grade 3–4 toxicities occurred and no patient had to discontinue the treatment due to severe adverse events. Conclusions: The results of the present study confirm the efficacy and safety of the two-drug combination regimen previously shown in a randomized clinical trial (Madeddu et al, Clinical Nutrition 31:176-182,2012). Therefore, this simple, feasible, effective, safe, with favorable cost-benefit profile, two-drug approach could be suggested in the clinical practice as a treatment for CACS.
A Combined Molecular and Clinical Prognostic Index For Relapse and Survival In Cytogenetically Normal AML (PINA)
Authors: Friederike Pastore, Annika Dufour, Tobias Benthaus, Klaus H. Metzeler, Kati Maharry, Stephanie Schneider, Bianka Ksienzyk, Gudrun Mellert, Evelyn Zellmeier, Purvi M. Kakadia, Michael Unterhalt, Michaela Feuring-Buske, Christian Buske, Jan Braess, Cristina Sauerland, Achim Heinecke, Utz Krug, Wolfgang E. Berdel, Thomas Büchner, Bernhard J. Woermann, Wolfgang Hiddemann, Stefan K. Bohlander, Guido Marcucci, Karsten Spiekermann, Clara D. Bloomfield, Eva Hoster
Journal: Blood (2013)
Enzyme-Linked Immunosorbent Assay for Human Manganese-Containing Superoxide Dismutase and Its Content in Lung Cancer&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN4"&gt;4&lt;/xref&gt;
Authors: S Iizuka, N Taniguchi, A Makita
Journal: JNCI Journal of the National Cancer Institute (1984)

A manganese-containing superoxide dismutase (Mn-SOD) was purified from human liver. Polyclonal antibody for the Mn-SOD was prepared in goat, and a simple and specific enzyme-linked immunosorbent assay (ELISA) for the Mn-SOD was developed. This assay was found to be sensitive to nanogram amounts of the enzyme. With respect to Mn-SOD levels of normal lung tissues, a positive correlation (r=0.92, P<.001) was observed between the results of enzymatic assay and those of immunochemical assay by ELISA. In lung carcinoma tissue the enzyme activity was in the same order of magnitude as in uninvolved tissues. However, the enzyme content determined by ELISA was significantly higher in adenocarcinoma than in the uninvolved lung tissue, whereas no significant difference from the control was observed in other histologic types. The discrepancy between the enzyme activity and immunoreactive content suggested that in the adenocarcinoma of the lung an immunoreactive but enzymatically inactive Mn-SOD protein existed and that a high content of this enzyme was characteristic of lung adenocarcinoma.
Hair and Scalp Care in African American Women Who Exercise
Authors: Christine S. Ahn, Poonkiat Suchonwanit, Capri G. Foy, Phillip Smith, Amy J. McMichael
Journal: JAMA Dermatology (2016)

This study surveys physically active black women to determine the most common hair care practices used to accommodate exercise, and seeks to provide recommendations for ideal regimens for hair and scalp care during and after exercise.
Emergency and elective pulmonary surgical resection in haematological patients with invasive fungal infections: a report of 50 cases in a single centre
Authors: M.-L. Chretien, C. Legouge, P.-B. Pagès, I. Lafon, E. Ferrant, A. Plocque, C. Favennec, L. Estivalet, E. Bottolier-Lemallaz, F. Dalle, J.-N. Bastie, A. Bernard, D. Caillot
Journal: Clinical Microbiology and Infection (2016)